Authors
Melissa Harbrücker, Sebastian Hoffmann, Johannes Tobias Thiel, Noelle Samira Jacob-Rehfeld, Sebastian M Christ, Adrien Daigeler, Anna Duprée, Felix Ehret, Anne Flörcken, Peter Hohenberger, Bernd Kasper, Christoph Reißfelder, Jens Jakob, Ulrich Kneser, Felix Strübing, Jana Käthe Striefler, Siyer Roohani
Published in
Radiation oncology (London, England). Volume 21. Issue 1. Aug 19, 2026. Epub Aug 19, 2026.
Abstract
To evaluate oncological outcomes and prognostic factors in patients with radiation-associated angiosarcoma (RAAS) treated at referral centers.
We conducted a multi-institutional retrospective cohort study of patients with histopathologically confirmed primary or recurrent RAAS treated at four referral centers in Germany. Endpoints were overall survival (OS) and progression-free survival (PFS), estimated using the Kaplan-Meier method. Prognostic factors were assessed using multivariable Cox regression.
Among 71 patients (97.2% female; median age 69 years), 90% had a history of breast cancer treated with radiotherapy (RT). RAAS developed after a mean latency of 7 years, with a median RT dose of 59.4 Gy. Over a median follow-up of 13.0 months, OS reached a median of 41.7 months, with 1- and 2-year rates of 82.9% and 61.7%, respectively. Median PFS was 9.5 months, with 1- and 2-year rates of 43.7% and 27.1%. Larger tumor size (HR 1.09, p = 0.032) and metastatic disease at diagnosis (HR 2.98, p = 0.003) were associated with worse OS.
RAAS are aggressive, frequently relapsing malignancies occurring years after RT. Larger tumor size and metastatic presentation are associated with worse OS. Multi-institutional and translational studies are needed to clarify disease biology, refine risk factors, and guide treatment strategies.
PMID:
42618930
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0